NASDAQ:CYAD Celyad Oncology (CYAD) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free CYAD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.40▼$0.6550-Day Range$0.59▼$0.8552-Week Range$0.46▼$3.07Volume3,009 shsAverage VolumeN/AMarket Capitalization$15.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Celyad Oncology alerts: Email Address Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here About Celyad Oncology Stock (NASDAQ:CYAD)Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Read More Ad Paradigm PressNever use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...Watch my unredacted video about what I think is coming next right here CYAD Stock News HeadlinesApril 4, 2024 | finance.yahoo.comCelyad Oncology Reports Full Year 2023 Financial Results and Recent Business HighlightsMarch 29, 2024 | seekingalpha.comCSBR Champions Oncology, Inc.May 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).January 17, 2024 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology provides fourth quarter 2023 business update and 2024 outlookJanuary 16, 2024 | finance.yahoo.comCelyad Oncology provides fourth quarter 2023 business update and 2024 outlookDecember 17, 2023 | businesswire.comCelyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)December 4, 2023 | finance.yahoo.comCelyad Announces Management ChangeNovember 14, 2023 | tmcnet.comInformation on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 MayMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).November 11, 2023 | lse.co.ukCelyad Oncology Share Price (CYAD.BR)November 9, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology reports third quarter 2023 financial results and recent business highlightsNovember 9, 2023 | finance.yahoo.comCelyad Oncology reports third quarter 2023 financial results and recent business highlightsSeptember 26, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology announces the termination of its American Depository Receipt programSeptember 25, 2023 | marketwatch.comCelyad Oncology to Terminate ADR ProgramSeptember 25, 2023 | finance.yahoo.comCelyad Oncology announces the termination of its American Depository Receipt programSeptember 15, 2023 | finance.yahoo.comCelyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLCSeptember 12, 2023 | businesswire.comCelyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SASeptember 12, 2023 | ca.finance.yahoo.comCelyad Oncology SA (CYAD.BR)September 7, 2023 | finance.yahoo.comCelyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLCSeptember 4, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology Reports First Half 2023 Financial Results and Recent Business HighlightsSeptember 4, 2023 | finance.yahoo.comCelyad Oncology Reports First Half 2023 Financial Results and Recent Business HighlightsSeptember 4, 2023 | investing.comCelyad Oncology (CYADY) Earnings Dates & ReportsAugust 29, 2023 | finance.yahoo.comCelyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments From Historical ShareholdersAugust 25, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholdersJuly 19, 2023 | investing.comCelyad Oncology SA (CYADY)May 16, 2023 | finanznachrichten.deCelyad Oncology SA: Celyad Oncology announces receipt of Nasdaq delisting noticeMay 15, 2023 | finance.yahoo.comCelyad Oncology Announces Receipt of Nasdaq Delisting NoticeSee More Headlines Receive CYAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYAD CUSIPN/A CIK1637890 Webwww.celyad.com Phone(210) 039-4100Fax321-039-4141Employees95Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales144.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book3.00Miscellaneous Outstanding Shares26,520,000Free Float26,276,000Market Cap$15.91 million OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesGeorges RawadiChief Executive Officer & Executive DirectorDavid GeorgesVice President-Finance & AdministrationEytan BremanDirector-Research & DevelopmentAn PhanHead-LegalKey CompetitorsFSD PharmaNASDAQ:HUGECocrystal PharmaNASDAQ:COCPAytu BioPharmaNASDAQ:AYTUNeuroBo PharmaceuticalsNASDAQ:NRBOVBI VaccinesNASDAQ:VBIVView All Competitors CYAD Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Celyad Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX). When did Celyad Oncology IPO? Celyad Oncology (CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers. This page (NASDAQ:CYAD) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celyad Oncology SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
